Genmab A/S Share Price Nasdaq
Stocks
GMAB
US3723032062
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Cboe BZX
18:09:36 13/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 31.30 USD | -0.40% |
|
+4.84% | +1.54% |
| 08-12 | BNP Paribas Initiates Genmab at Outperform, With $40 Price Target | MT |
| 08-12 | Nordic stocks in North America: AstraZeneca fell 1.0% | FW |
| Market Cap | 122B 18.76B 16.26B 15.25B 13.9B 26.16B 1,791B 26.58B 180B 70.08B 896B 70.44B 68.91B 2,990B | P/E 2026 * |
25.7x | P/E 2027 * | 18.1x |
|---|---|---|---|---|---|
| Enterprise Value | 141B 21.79B 18.89B 17.71B 16.14B 30.38B 2,080B 30.86B 208B 81.39B 1,041B 81.8B 80.03B 3,473B | EV / Sales 2026 * |
4.87x | EV / Sales 2027 * | 3.94x |
| Free-Float |
95.41% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Genmab A/S
| 1 day | -0.40% | ||
| 1 week | +4.84% | ||
| Current month | +8.33% | ||
| 1 month | +8.59% | ||
| 3 months | +17.80% | ||
| 6 months | +4.15% | ||
| Current year | +1.54% |
| 1 week | 30.52 |  | 31.79 |
| 1 month | 27.86 | | 31.79 |
| Current year | 23.62 | | 35.43 |
| 1 year | 22.48 | | 35.43 |
| 3 years | 17.24 | | 39.53 |
| 5 years | 17.24 | | 49.07 |
| 10 years | 12.1 | | 49.07 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 31/05/2010 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 29/02/2020 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 15/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 31/10/2003 | |
| Director/Board Member | 58 | 31/12/2014 | |
| Director/Board Member | 75 | 31/12/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.40% | +4.84% | - | - | 18.77B | |
| +2.07% | +10.05% | +77.41% | +106.53% | 70.1B | |
| -0.87% | +0.08% | +36.96% | +65.04% | 54.93B | |
| -4.01% | -4.10% | +3.45% | +470.00% | 28.89B | |
| +0.04% | +12.56% | +54.67% | +5.47% | 23.9B | |
| +0.12% | +1.86% | -17.64% | -13.55% | 23.3B | |
| +0.35% | +8.24% | +252.94% | +466.50% | 18.41B | |
| -0.59% | +7.88% | +40.87% | -20.12% | 18.77B | |
| -0.57% | +6.85% | +30.20% | +580.70% | 16.1B | |
| +0.82% | -2.97% | +31.59% | +135.47% | 12.48B | |
| Average | -0.29% | +8.19% | +56.72% | +199.56% | 29.65B | |
| Weighted average by Cap. | -0.08% | +8.03% | +55.29% | +163.68% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 29.01B 4.48B 3.88B 3.64B 3.32B 6.24B 427B 6.34B 42.82B 16.72B 214B 16.8B 16.44B 713B | 33.71B 5.2B 4.51B 4.23B 3.85B 7.25B 496B 7.37B 49.76B 19.43B 248B 19.53B 19.1B 829B |
| Net income | 4.94B 762M 661M 619M 565M 1.06B 72.75B 1.08B 7.29B 2.85B 36.42B 2.86B 2.8B 121B | 7.17B 1.11B 959M 899M 820M 1.54B 106B 1.57B 10.59B 4.13B 52.87B 4.15B 4.06B 176B |
| Net Debt | 19.62B 3.03B 2.62B 2.46B 2.24B 4.22B 289B 4.29B 28.96B 11.31B 145B 11.36B 11.12B 482B | 11.13B 1.72B 1.49B 1.4B 1.27B 2.39B 164B 2.43B 16.43B 6.41B 82.03B 6.45B 6.31B 274B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/08/26 | US$31.29 | -0.43% | 1,852,686 |
| 12/08/26 | US$31.42 | +1.85% | 3,516,973 |
| 11/08/26 | US$30.85 | -0.06% | 1,587,051 |
| 10/08/26 | US$30.87 | -1.22% | 2,799,566 |
| 07/08/26 | US$31.25 | +4.76% | 3,507,362 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
Select your edition
All financial news and data tailored to specific country editions
